Dapsone as treatment adjunct in ARDS.
Exp Lung Res
; 46(5): 157-161, 2020.
Article
in English
| MEDLINE | ID: covidwho-1017073
ABSTRACT
Multiple pharmacological interventions tested over the last decades have failed to reduce ARDS mortality. This short note recounts past data indicating that (i) neutrophils home along an IL-8 gradient, (ii) in ARDS, massive neutrophil accumulation and degranulation in and along bronchoalveolar spaces contributes to damage and hypoxia, (iii) large increases in IL-8 are one of the chemotaxic signals drawing neutrophils to the ARDS lung, and (iv) old data from dermatology and glioblastoma research showed that the old drug against Hansen's disease, dapsone, inhibits neutrophils' chemotaxis to IL-8. Therefore dapsone might lower neutrophils' contributions to ARDS lung pathology. Dapsone can create methemoglobinemia that although rarely problematic it would be particularly undesirable in ARDS. The common antacid drug cimetidine lowers risk of dapsone related methemoglobinemia and should be given concomitantly.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
Dapsone
/
Anti-Infective Agents
/
Neutrophils
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Exp Lung Res
Year:
2020
Document Type:
Article
Affiliation country:
01902148.2020.1753266
Similar
MEDLINE
...
LILACS
LIS